Result:Good· Market: Down#Margin expansion
| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 185.24 | 4.4% | 0.3% |
| Total Income | 185.85 | 5.6% | 0.5% |
| Expenditure | 170.80 | 5.1% | 3.5% |
| PBT | 15.05 | 11.1% | 51.7% |
| Net Profit | 11.21 | 1.9% | 47.3% |
| OPM | 9.15% | 0.75pp | 2.76pp |
| NPM | 6.03% | 0.23pp | 1.96pp |
| EPS | 1.12 | 1.8% | 47.4% |
Pharma adjusted PAT grew 47% YoY on flat revenue, driven by strong OPM expansion (6.4%→9.2%) rather than core top-line growth, which is healthy but caps it short of a standout.
Informational and educational content only. Not investment advice.